LLY

1,042.71

+1.91%↑

JNJ

244.52

+1.59%↑

ABBV

225.66

+2.1%↑

NVS

161.62

+1.13%↑

MRK

120.77

+1.83%↑

LLY

1,042.71

+1.91%↑

JNJ

244.52

+1.59%↑

ABBV

225.66

+2.1%↑

NVS

161.62

+1.13%↑

MRK

120.77

+1.83%↑

LLY

1,042.71

+1.91%↑

JNJ

244.52

+1.59%↑

ABBV

225.66

+2.1%↑

NVS

161.62

+1.13%↑

MRK

120.77

+1.83%↑

LLY

1,042.71

+1.91%↑

JNJ

244.52

+1.59%↑

ABBV

225.66

+2.1%↑

NVS

161.62

+1.13%↑

MRK

120.77

+1.83%↑

LLY

1,042.71

+1.91%↑

JNJ

244.52

+1.59%↑

ABBV

225.66

+2.1%↑

NVS

161.62

+1.13%↑

MRK

120.77

+1.83%↑

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

12.78 -8.39

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

12.4

Max

13.54

Galvenie mērījumi

By Trading Economics

Ienākumi

1.4M

676K

Pārdošana

961K

18M

P/E

Sektora vidējais

48.528

121.746

EPS

-0.034

Dividenžu ienesīgums

0.48

Peļņas marža

3.67

Darbinieki

212

EBITDA

-3M

2.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+34.75% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.26%

Nākamie ieņēmumi

2026. g. 2. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-84M

284M

Iepriekšējā atvēršanas cena

21.17

Iepriekšējā slēgšanas cena

12.78

Ziņu noskaņojums

By Acuity

40%

60%

116 / 352 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 11. febr. 23:47 UTC

Karstas akcijas

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

2026. g. 11. febr. 22:59 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Grab Holdings to Buy U.S.-Based Stash Financial

2026. g. 11. febr. 23:54 UTC

Peļņas

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

2026. g. 11. febr. 23:50 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 11. febr. 23:50 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

2026. g. 11. febr. 23:49 UTC

Peļņas

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

2026. g. 11. febr. 23:45 UTC

Peļņas

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

2026. g. 11. febr. 23:42 UTC

Peļņas

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

2026. g. 11. febr. 23:41 UTC

Peļņas

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

2026. g. 11. febr. 23:40 UTC

Peļņas

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

2026. g. 11. febr. 23:35 UTC

Tirgus saruna

Gold Falls on Prospects of Long Fed Pause -- Market Talk

2026. g. 11. febr. 23:18 UTC

Tirgus saruna

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

2026. g. 11. febr. 23:14 UTC

Tirgus saruna

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

2026. g. 11. febr. 22:59 UTC

Peļņas

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

2026. g. 11. febr. 22:59 UTC

Peļņas

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

2026. g. 11. febr. 22:59 UTC

Peļņas

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

2026. g. 11. febr. 22:58 UTC

Peļņas

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

2026. g. 11. febr. 22:57 UTC

Peļņas

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

2026. g. 11. febr. 22:54 UTC

Peļņas

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

2026. g. 11. febr. 22:53 UTC

Peļņas

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

2026. g. 11. febr. 22:47 UTC

Peļņas

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

2026. g. 11. febr. 22:47 UTC

Peļņas

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

2026. g. 11. febr. 22:23 UTC

Peļņas

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

2026. g. 11. febr. 22:22 UTC

Peļņas

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

2026. g. 11. febr. 22:22 UTC

Peļņas

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

2026. g. 11. febr. 22:19 UTC

Peļņas

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

2026. g. 11. febr. 22:18 UTC

Peļņas

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

2026. g. 11. febr. 22:18 UTC

Peļņas

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

2026. g. 11. febr. 22:18 UTC

Peļņas

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

2026. g. 11. febr. 22:16 UTC

Peļņas

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

34.75% augšup

Prognoze 12 mēnešiem

Vidējais 19 USD  34.75%

Augstākais 19 USD

Zemākais 19 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

2

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

116 / 352 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat